Novo Nordisk to acquire liver disease drugmaker Akero Therapeutics for up to $5.2 billion
Novo Nordisk announced Thursdsay that it intends to acquire Akero Therapeutics for up to $5.2 billion.
Novo said it would pay $54 per share for Akero, a 15% premium to its $46.49 closing price in Wednesday, for a total of $4.7 billion.
Akero’s efruxifermin (EFX) treats a liver disease known as MASH, or metabolic dysfunction-associated steatohepatitis. The company is currently conducting late-stage trials of the drug. Shareholders will receive another $500 million if US regulators approve EFX to treat compensated cirrhosis brought about by MASH.
Akero rose about 18% in premarket trading.
Roche announced in September that it would buy another MASH drugmaker, 89bio, for $2.4 billion. GSK in July completed a $1.2 billion deal to license Boston Pharmaceuticals’ MASH drug.
Novo, the maker of Ozempic and Wegovy, has been struggling to spark sales growth amid increased competition from other weight-loss drugs and copycat versions of its drugs. The Danish drugmaker, which is down more than 30% for the year, slipped about 1% in premarket trading.